IGI Logo

Zydus Lifesciences is currently trading at Rs. 636.30, up by 2.80 points or 0.44% from its previous closing of Rs. 633.50 on the BSE.

The scrip opened at Rs. 636.00 and has touched a high and low of Rs. 644.15 and Rs. 634.75 respectively. So far 13450 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022.

Last one week high and low of the scrip stood at Rs. 648.70 and Rs. 630.15 respectively. The current market cap of the company is Rs. 64538.14 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.95% and 7.07% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methylene Blue Injection, 10mg/2ml and 50mg/5ml. Zydus’ Methylene Blue Injection, 10mg/2ml and 50mg/5ml is the generic version of the Reference Listed Drug (RLD) ProvayBlue Injection.

The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation. From a hospital perspective, vial presentation is an affordable option with significant benefit and advantage. Vial presentation has no risk of Glass particulate contamination like in ampoules and provides various benefits like ease of use, handlings and flexible option with reduced dose waste.

Methylene Blue Injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Methylene Blue Injection, 10mg/2ml and 50mg/5ml had an annual sale of around $73.4 million in the United States (IQVIA MAT October-2023).

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.